Results 71 to 80 of about 4,770 (180)

Assessing Dietary Patterns and Composition Among Adults With Cystic Fibrosis Taking Highly Effective Modulator Therapy

Pediatric Pulmonology, Volume 61, Issue 3, March 2026.
ABSTRACT Background The metabolic impact of poor diet quality in cystic fibrosis (CF), coupled with a rise in obesity and modulator‐induced weight gain, is a growing concern. Our study aimed to understand knowledge and perspectives regarding dietary changes on modulators, and how measured nutrient intake changes with different dietary patterns in ...
Julianna Bailey, Natalie R. Rose, Ashritha R. Chalamalla, Justin D. Anderson, Elizabeth Baker, Jennifer S. Guimbellot   +5 more
wiley   +1 more source

Efficacy of Trikafta (ELX/TEZ/IVA) & Symdeko (TEZ/IVA) in Treating Cystic Fibrosis with F508del Allele: A Systematic Review and Meta-analysis

Thoracic Research and Practice
The objective of the study was to assess and compare the efficacy of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) treatment with TEZ/IVA treatment in individuals diagnosed with cystic fibrosis (CF) and carrying the F508del allele.
Kainat Hussain, Sonali Karhana, Aakriti Garg, Mohd Ashif Khan   +3 more
doaj   +1 more source

Elexacaftor/tezacaftor/ivacaftor as rescue therapy in a patient with the cystic fibrosis genotype F508DEL/G1244E

Clinical Case Reports, 2021
Elexacaftor/tezacaftor/ivacaftor (ETI) is a cystic fibrosis (CF) transmembrane regulator (CFTR) modulator. It is known to be efficacious in stable patients with severe pneumopathy, but there are few data concerning its effectiveness during acute ...
Donatello Salvatore, Carmela Colangelo, Michele D’Andria, Giovanni Marsicovetere, Domenica Passarella   +4 more
doaj   +1 more source

Frequency of CFTR variants in southern Brazil and indication for modulators therapy in patients with cystic fibrosis

Genetics and Molecular Biology, 2021
This is a descriptive cross-sectional study that aims to determine the distribution of the CFTR causing variant in a group of patients at a cystic fibrosis (CF) center in southern Brazil, as well as to describe causing variants that are treatable with ...
Eliandra da Silveira Lima, Luíse Sgarabotto Pezzin, Ana Carolina Fensterseifer, Leonardo Araújo Pinto   +3 more
doaj   +1 more source

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with Cystic Fibrosis following liver transplantation:A systematic review [PDF]

BACKGROUND & AIMS: Cystic Fibrosis (CF) liver disease progresses to liver failure requiring transplantation in about 3 % of patients, 0.7 % of CF patients are post liver transplant.
Brugha, Rossa, Indolfi, Giuseppe, Terlizzi, Vito, Testa, Ilaria, Verkade, Henkjan J   +4 more
core   +1 more source

Long-Term Follow-Up of Health-Related Quality of Life and Short-Term Intervention with CFTR Modulator Therapy in Adults with Cystic Fibrosis: Evaluation of Changes over Several Years with or without 33 Weeks of CFTR Modulator Therapy [PDF]

, 2023
Background Longitudinal data on changes in health-related quality of life (HRQoL) in adult people with cystic fibrosis (pwCF) and the longitudinal effects of Elexacaftor/Tezacaftor/Ivacaftor therapy (ETI) on HRQoL or HRQoL domains are currently scarce ...
Blosch, Christopher, Brinkmann, Folke, Dillenhoefer, Stefanie, Gruber, Wolfgang, Koerner-Rettberg, Cordula, Mellies, Uwe, Olivier, Margarete, Stehling, Florian, Sutharsan, Sivagurunathan, Taube, Christian, Welsner, Matthias   +10 more
core   +1 more source

Disparities in Access to Cystic Fibrosis Therapy Across Countries

Pediatric Pulmonology, Volume 61, Issue 3, March 2026.
ABSTRACT Cystic fibrosis has been transformed by the development of CFTR modulator therapies, with substantial improvements in survival and quality of life. However, access to these therapies remains profoundly unequal worldwide. The greatest benefits have been realized in high‐income countries, while people with cystic fibrosis in low‐ and middle ...
Bulent Karadag
wiley   +1 more source

Standards for the care of people with cystic fibrosis; establishing and maintaining health [PDF]

, 2023
This is the second in a series of four papers updating the European Cystic Fibrosis Society (ECFS) standards for the care of people with CF. This paper focuses on establishing and maintaining health.
Addy, C, Bell, S, Bertrand, DP, Bevan, A, Borawska, U, Brown, C, Burgel, PR, Button, B, Castellani, C, Chansard, A, Chilvers, M, Davies, G, Davies, J, De Boeck, K, Declercq, D, Doumit, M, Drevinek, P, Fajac, I, Gartner, S, Georgiopoulos, A, Gramegna, A, Gursli, S, Hansen, CM, Hug, M, Lammertyn, E, Landau, EC, Langley, R, Mayer-Hamblett, N, Middleton, A, Middleton, P, Mielus, M, Morrison, L, Munck, A, Plant, B, Ploeger, M, Pressler, T, Quon, BS, Radtke, T, Saynor, ZL, Shufer, I, Smith, C, Smyth, AR, Southern, K, Van Koningsbruggen-Rietschel, S   +43 more
core  

Open Systems Pharmacology Community Conference (OSP‐CC) Proceedings 2025

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT Developed at Bayer Technology Services, PK‐Sim and MoBi transitioned into the Open Systems Pharmacology (OSP) Suite, released as free open‐source software in 2017. An active community with stakeholders from academia, industries, and regulators contributes to the continuous improvement of open‐source model‐informed drug development (MIDD). This
Henrik Cordes, Pieter Annaert, Pavel Balazki, Salih Benamara, Rodolfo Hernandes Bonan, Andrew Butler, Marylore Chenel, Yunhai Cui, André Dallmann, Wilhelmus E. A. de Witte, Cleo Demeester, Denise Feick, Florence Gattacceca, René Geci, Grégori Gerebtzoff, Andrea Gruber, Mariana Guimarães, Abdullah Hamadeh, Nina Hanke, Manuel Ibarra, Ibrahim Ince, Tobias Kanacher, Lars Kuepfer, Felix Mil, Ghazal Montaseri, Nina Nauwelaerts, Susana Proenca, Stephan Schaller, Jan Frederik Schlender, Annika R. P. Schneider, Erik Sjögren, Juri Solodenko, Alexander Staab, Paul Vrenken, Carla Troisi, Donato Teutonico   +35 more
wiley   +1 more source

Sodium Glucose‐Like Co‐Transporter 2 Inhibitor (SGLT2i) Use in Adults With Cystic Fibrosis

Respirology Case Reports, Volume 14, Issue 3, March 2026.
Use of sodium glucose‐like co‐transporter 2 inhibitors in people with cystic fibrosis may be considered for glycaemic, renal and cardiac benefits. We described safe, tolerable and effective use in three adults with CF. ABSTRACT Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) also called flozins or gliflozins have been demonstrated to have multi ...
Ellie Johnson, Angela Matson, Robyn Cobb, Shanal Kumar   +3 more
wiley   +1 more source